AR076341A1 - Terapias basadas en ligados de receptores quimiosensoriales. metodo de tratamiento. composicion - Google Patents
Terapias basadas en ligados de receptores quimiosensoriales. metodo de tratamiento. composicionInfo
- Publication number
- AR076341A1 AR076341A1 ARP100101302A ARP100101302A AR076341A1 AR 076341 A1 AR076341 A1 AR 076341A1 AR P100101302 A ARP100101302 A AR P100101302A AR P100101302 A ARP100101302 A AR P100101302A AR 076341 A1 AR076341 A1 AR 076341A1
- Authority
- AR
- Argentina
- Prior art keywords
- composition
- chemosensory receptor
- diabetes
- ligand
- subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Composiciones y métodos para el tratamiento de diabetes, obesidad y otras enfermedades, trastornos o condiciones metabolicas con ligandos de receptores quimiosensoriales. Reivindicacion 1: Un método de tratamiento de una condicion asociada con un receptor quimiosensorial en un sujeto, caracterizado porque comprende la administracion de al menos un ligando del receptor quimiosensorial al sujeto. Reivindicacion 10: El método de cualquiera de las reivindicaciones 1-9, caracterizado porque además comprende la administracion de al menos un metabolito de un receptor quimiosensorial que corresponde a por lo menos un ligando del receptor quimiosensorial. Reivindicacion 35: Un método para modular el perfil hormonal del intestino inferior, caracterizado porque comprende la administracion de una composicion que comprende al menos un ligando del receptor quimiosensorial en el intestino inferior de un sujeto. Reivindicacion 44: Una composicion, caracterizada porque comprende al menos un ligando del receptor quimiosensorial, en donde la composicion se formula para su liberacion en el intestino inferior y con lo cual la composicion es eficaz para el tratamiento de una condicion asociada con un receptor quimiosensorial. Reivindicacion 64: La composicion de cualquiera de las reivindicaciones 44-63, caracterizada porque dicha composicion además comprende un recubrimiento entérico. Reivindicacion 65: La composicion de cualquiera de las reivindicaciones 44-63, caracterizada porque la composicion además comprende un recubrimiento entérico y no requiere la absorcion de los agonistas del receptor quimiosensorial. Reivindicacion 66: La composicion de cualquiera de las reivindicaciones 44-63, caracterizada porque dicha composicion además comprende un sistema de liberacion sincronizada. Reivindicacion 67: La composicion de cualquiera de las reivindicaciones 44-66, caracterizada porque la condicion asociada con un receptor quimiosensorial se selecciona entre síndrome metabolico, diabetes tipo I, diabetes tipo II, condiciones asociadas con la diabetes, obesidad, intolerancia a glucosa, diabetes mellitus gestacional (GDM), dislipidemia, dislipidemia de post-ingesta, enfermedad de intestino inflamatorio (IBD), incluyendo colitis ulcerosa y enfermedad de Crohn, síndrome de intestino irritable (IBS), síndrome de intestino corto, síndrome de ovario poliquístico (PCOS), enfermedad de hígado graso no alcoholico (NAFL), esteatohepatitis no alcoholica (NASH), anorexia, adiccion a la comida, pérdida de peso, depresion o un trastorno del humor.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17065709P | 2009-04-20 | 2009-04-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR076341A1 true AR076341A1 (es) | 2011-06-01 |
Family
ID=42981433
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100101302A AR076341A1 (es) | 2009-04-20 | 2010-04-20 | Terapias basadas en ligados de receptores quimiosensoriales. metodo de tratamiento. composicion |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP2421524B1 (es) |
JP (1) | JP2012524125A (es) |
CN (1) | CN102481276A (es) |
AR (1) | AR076341A1 (es) |
AU (1) | AU2010239311B2 (es) |
BR (1) | BRPI1013856A2 (es) |
CA (1) | CA2758976C (es) |
EA (1) | EA201101524A1 (es) |
WO (1) | WO2010123930A2 (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9901551B2 (en) * | 2009-04-20 | 2018-02-27 | Ambra Bioscience Llc | Chemosensory receptor ligand-based therapies |
US20130281394A1 (en) * | 2010-10-19 | 2013-10-24 | Elcelyx Therapeutics, Inc. | Chemosensory Receptor Ligand-Based Therapies |
EP2629617A4 (en) * | 2010-10-19 | 2014-08-27 | Elcelyx Therapeutics Inc | THERAPIES BASED ON CHEMOSOUS RECEPTOR LIGANDS |
WO2012054528A2 (en) * | 2010-10-19 | 2012-04-26 | Elcelyx Therapeutics, Inc. | Chemosensory receptor ligand-based therapies |
US9486463B2 (en) | 2010-10-19 | 2016-11-08 | Ambra Bioscience Llc | Chemosensory receptor ligand-based therapies |
US8796338B2 (en) | 2011-01-07 | 2014-08-05 | Elcelyx Therapeutics, Inc | Biguanide compositions and methods of treating metabolic disorders |
US9480663B2 (en) | 2011-01-07 | 2016-11-01 | Elcelyx Therapeutics, Inc. | Biguanide compositions and methods of treating metabolic disorders |
US9572784B2 (en) | 2011-01-07 | 2017-02-21 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
US11759441B2 (en) | 2011-01-07 | 2023-09-19 | Anji Pharmaceuticals Inc. | Biguanide compositions and methods of treating metabolic disorders |
KR20140035331A (ko) | 2011-01-07 | 2014-03-21 | 엘셀릭스 테라퓨틱스 인코포레이티드 | 화학감각 수용체 리간드-기반 요법 |
US9211263B2 (en) | 2012-01-06 | 2015-12-15 | Elcelyx Therapeutics, Inc. | Compositions and methods of treating metabolic disorders |
KR20190120430A (ko) | 2012-01-06 | 2019-10-23 | 엘셀릭스 테라퓨틱스 인코포레이티드 | 바이구아나이드 조성물 및 대사 장애를 치료하는 방법 |
JP6175074B2 (ja) | 2012-01-06 | 2017-08-02 | エルセリクス セラピューティクス インコーポレイテッド | 代謝障害を治療するための組成物および方法 |
US10774127B2 (en) | 2016-10-12 | 2020-09-15 | University Of Copenhagen | Peptide dual agonists of GIPR and GLP2R |
CN109381471B (zh) * | 2017-08-08 | 2022-06-03 | 浙江养生堂天然药物研究所有限公司 | 包含柠檬苦素类化合物和双胍类化合物的组合产品 |
US10792266B2 (en) | 2017-10-23 | 2020-10-06 | Epitracker, Inc. | Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome |
CN107669694A (zh) * | 2017-10-23 | 2018-02-09 | 重庆市沙坪坝区人民医院 | 莱苞迪甙a在制备预防或治疗骨质疏松症药物中的应用 |
EP3934639A4 (en) * | 2019-03-04 | 2023-01-11 | Epitracker, Inc. | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE DISORDERS, BEHAVIORAL DISORDERS AND CHRONIC PAIN |
CN110327355B (zh) * | 2019-08-12 | 2021-06-04 | 浙江养生堂天然药物研究所有限公司 | 包含柠檬苦素类化合物和sglt-2抑制剂的组合产品 |
CN110302386B (zh) * | 2019-08-12 | 2021-05-04 | 浙江养生堂天然药物研究所有限公司 | 包含柠檬苦素类化合物和磺酰脲类药物的组合产品 |
CN110327356B (zh) * | 2019-08-12 | 2021-06-04 | 浙江养生堂天然药物研究所有限公司 | 包含柠檬苦素类化合物和α-糖苷酶抑制剂的组合产品 |
CN110314233B (zh) * | 2019-08-12 | 2021-07-23 | 浙江养生堂天然药物研究所有限公司 | 包含柠檬苦素类化合物和dpp-4抑制剂的组合产品 |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
JPS58403B2 (ja) | 1975-07-24 | 1983-01-06 | 武田薬品工業株式会社 | L− アスコルビンサンセイザイノ セイゾウホウ |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
JPS5825980B2 (ja) | 1976-02-12 | 1983-05-31 | ヤマサ醤油株式会社 | サイクリックヌクレオチドの定量法 |
US4434153A (en) | 1982-03-22 | 1984-02-28 | Alza Corporation | Drug delivery system comprising a reservoir containing a plurality of tiny pills |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
JPS62195323A (ja) | 1986-02-24 | 1987-08-28 | Eisai Co Ltd | 胃内滞留型粒子 |
US4915952A (en) | 1987-02-27 | 1990-04-10 | Alza Corporation | Composition comprising drug, HPC, HPMC and PEO |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
US5135757A (en) | 1988-09-19 | 1992-08-04 | Edward Mendell Co., Inc. | Compressible sustained release solid dosage forms |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
US5007790A (en) | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5401629A (en) | 1990-08-07 | 1995-03-28 | The Salk Institute Biotechnology/Industrial Associates, Inc. | Assay methods and compositions useful for measuring the transduction of an intracellular signal |
CA2106847A1 (en) | 1991-04-05 | 1992-10-06 | Linda B. Buck | Odorant receptors and uses thereof |
DE69206993T2 (de) | 1991-07-19 | 1996-05-30 | Uniroyal Chem Co Inc | Zusammensetzungen zur verwendung von filmen auf saatgut |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
DE69322077T2 (de) | 1992-03-25 | 1999-04-08 | Depomed Inc | Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe |
US5582837A (en) | 1992-03-25 | 1996-12-10 | Depomed, Inc. | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
FR2704146B1 (fr) | 1993-04-19 | 1995-07-13 | Cripdom | Microcapsules d'acide acétylsalicylique à libération contrôlée. |
US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
US5773025A (en) | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
US5589194A (en) | 1993-09-20 | 1996-12-31 | Minnesota Mining And Manufacturing Company | Method of encapsulation and microcapsules produced thereby |
US5451409A (en) | 1993-11-22 | 1995-09-19 | Rencher; William F. | Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends |
IL108205A0 (en) | 1993-12-28 | 1994-04-12 | Yeda Res & Dev | Olfactory genes and receptors |
US5691188A (en) | 1994-02-14 | 1997-11-25 | American Cyanamid Company | Transformed yeast cells expressing heterologous G-protein coupled receptor |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
FR2725623A1 (fr) | 1994-10-18 | 1996-04-19 | Flamel Tech Sa | Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os |
MY113429A (en) | 1995-02-28 | 2002-02-28 | Univ Temple | Controlled release tablet containing swellable polyethylene oxide |
US5945125A (en) | 1995-02-28 | 1999-08-31 | Temple University | Controlled release tablet |
AU1118197A (en) | 1995-11-09 | 1997-05-29 | Johns Hopkins University School Of Medicine, The | Novel sperm receptors |
GB9523752D0 (en) | 1995-11-21 | 1996-01-24 | Pfizer Ltd | Pharmaceutical formulations |
US5783212A (en) | 1996-02-02 | 1998-07-21 | Temple University--of the Commonwealth System of Higher Education | Controlled release drug delivery system |
US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
US5874243A (en) | 1997-03-28 | 1999-02-23 | Smithkline Beecham Corporation | OLRCC15 receptor |
US6210710B1 (en) | 1997-04-28 | 2001-04-03 | Hercules Incorporated | Sustained release polymer blend for pharmaceutical applications |
ATE302597T1 (de) | 1997-06-06 | 2005-09-15 | Depomed Inc | Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung |
ES2234139T3 (es) | 1997-08-11 | 2005-06-16 | Alza Corporation | Forma de dosificacion de un agente activo de liberacion prolongada adaptada para la retencion gastrica. |
US6090411A (en) | 1998-03-09 | 2000-07-18 | Temple University | Monolithic tablet for controlled drug release |
US6538194B1 (en) | 1998-05-29 | 2003-03-25 | Catalysts & Chemicals Industries Co., Ltd. | Photoelectric cell and process for producing metal oxide semiconductor film for use in photoelectric cell |
FR2780405B1 (fr) | 1998-06-25 | 2001-12-28 | Centre Nat Rech Scient | Nouveaux recepteurs olfactifs et leurs utilisations |
TW514510B (en) | 1999-06-11 | 2002-12-21 | Tanita Seisakusho Kk | Method and apparatus for measuring distribution of body fat |
US6530886B1 (en) | 1999-10-08 | 2003-03-11 | Tanita Corporation | Method and apparatus for measuring subcutaneous fat using ultrasonic wave |
IL133196A0 (en) | 1999-11-29 | 2001-03-19 | Yissum Res Dev Co | Gastroretentive controlled release pharmaceutical dosage forms |
AU5125801A (en) | 2000-04-07 | 2001-10-23 | Senomyx Inc | T2r taste receptors and genes encoding same |
TW515705B (en) | 2000-05-31 | 2003-01-01 | Yamato Scale Co Ltd | Visceral fat meter |
US6955887B2 (en) * | 2001-03-30 | 2005-10-18 | Senomyx, Inc. | Use of T1R hetero-oligomeric taste receptor to screen for compounds that modulate taste signaling |
US7670627B2 (en) * | 2002-12-09 | 2010-03-02 | Salvona Ip Llc | pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients |
ATE480255T1 (de) | 2005-03-31 | 2010-09-15 | Amylin Pharmaceuticals Inc | Zusammensetzungen und verfahren zur kontrolle, prävention und behandlung von essstörungen |
US20080107787A1 (en) * | 2006-11-02 | 2008-05-08 | The Coca-Cola Company | Anti-Diabetic Composition with High-Potency Sweetener |
US9603848B2 (en) | 2007-06-08 | 2017-03-28 | Senomyx, Inc. | Modulation of chemosensory receptors and ligands associated therewith |
US20080305500A1 (en) * | 2007-06-08 | 2008-12-11 | Senomyx, Inc. | Novel cell-based assays for identifying enhancers or inhibitors of t1r taste receptors (t1r2/t1r3 sweet) and umami (t1r1/t1r3 umami) taste receptors |
US20080306076A1 (en) * | 2007-06-08 | 2008-12-11 | Senomyx, Inc. | Modulation of chemosensory receptors and ligands associated therewith |
US7928111B2 (en) * | 2007-06-08 | 2011-04-19 | Senomyx, Inc. | Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors |
-
2010
- 2010-04-20 CA CA2758976A patent/CA2758976C/en not_active Expired - Fee Related
- 2010-04-20 EA EA201101524A patent/EA201101524A1/ru unknown
- 2010-04-20 AU AU2010239311A patent/AU2010239311B2/en not_active Ceased
- 2010-04-20 WO PCT/US2010/031793 patent/WO2010123930A2/en active Application Filing
- 2010-04-20 JP JP2012507328A patent/JP2012524125A/ja active Pending
- 2010-04-20 CN CN201080028729XA patent/CN102481276A/zh active Pending
- 2010-04-20 EP EP10767661.1A patent/EP2421524B1/en not_active Not-in-force
- 2010-04-20 BR BRPI1013856A patent/BRPI1013856A2/pt not_active Application Discontinuation
- 2010-04-20 AR ARP100101302A patent/AR076341A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
BRPI1013856A2 (pt) | 2016-04-05 |
EP2421524A2 (en) | 2012-02-29 |
CA2758976A1 (en) | 2010-10-28 |
CN102481276A (zh) | 2012-05-30 |
EA201101524A1 (ru) | 2012-07-30 |
EP2421524A4 (en) | 2012-11-14 |
AU2010239311B2 (en) | 2014-05-22 |
JP2012524125A (ja) | 2012-10-11 |
EP2421524B1 (en) | 2018-08-08 |
WO2010123930A3 (en) | 2011-02-24 |
WO2010123930A2 (en) | 2010-10-28 |
AU2010239311A1 (en) | 2011-12-01 |
CA2758976C (en) | 2015-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR076341A1 (es) | Terapias basadas en ligados de receptores quimiosensoriales. metodo de tratamiento. composicion | |
PH12020551024A1 (en) | Incretin analogs and uses thereof | |
MY187988A (en) | Composition for treating hyperlipidemia comprising oxyntomodulin derivative | |
PH12020551025A1 (en) | Incretin analogs and uses thereof | |
PH12017500761A1 (en) | Co-agonists of glucagon and glp-1 receptors | |
CL2013000768A1 (es) | Composicion farmaceutica que comprende un compuesto derivado de (6s)-6-(2-hidroxi-2-metilpropil)-6-fenil-3-{(1s)-1-[4-(2-oxo-1,2-dihidropiridin-4-il)fenil]etil}-1,3-oxazin-2-ona y un segundo agente terapéutico; y su uso para prevenir o retrasar un trastorno asociado a diabetes mellitus 2 o tolerancia alterada a la glucosa. | |
MX2012011631A (es) | Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con el mismo. | |
MA33428B1 (fr) | Agonistes du gpr119 | |
EA201692214A1 (ru) | Вещества, связывающие ядерные рецепторы | |
TW200738269A (en) | Oral delivery of therapeutic agents using tight junction agonists | |
MY150082A (en) | Trans-clomiphene for metabolic syndrome | |
UY32167A (es) | Nuevos derivados de 2-amidotiadiazol | |
CL2011002597A1 (es) | Compuestos derivados de rifamicina; procedimiento de preparacion; composicion farmaceutica; su uso para tratar, prevenir o aliviar sobrecrecimiento bacteriano en trastornos intestinales tales como sindrome de colon irritable, diarrea del viajante, enfermedad de crohn, encefalopatia hepatica y enteritis. | |
PH12014502448A1 (en) | Pharmaceutical combinations for the treatment of metabolic disorders | |
MX365108B (es) | Derivados piperidina para agonista gpr119. | |
AR077546A1 (es) | Formulaciones de comprimidos de 3-cianoquinolina y usos de los mismos | |
WO2013044044A3 (en) | Methods of treating fatty liver disease with helminth-derived glycan-containing compounds | |
JP2014210824A5 (es) | ||
AR077714A1 (es) | Derivados de 3-heteroaril-metil-imidazo-(1,2-b) -piridazin-6-ilo | |
RU2013142888A (ru) | Новые азаспиродеканоны | |
BR112012006069A8 (pt) | Método para tratar ou prevenir constipação induzida e disfunção intestinal induzida por opióide em um humano, e, uso de uma quantidade terapeuticamente efetiva de composto | |
MX2022000388A (es) | Terapia de combinacion de agonista de gpr119 e inhibidores de dpp-4. | |
AR102546A1 (es) | Composiciones nutricionales que contienen un prebiótico y lactoferrina y método para la modulación de la expresión del receptor serotoninérgico | |
GR20110100714A (el) | Μεθοδος δημιουργιας/αναπτυξης παγκρεατικων νησιδων. λειτουργικη επανεισαγωγη στον οργανισμο. δημιουργια κρυοτραπεζας νησιδων langerhans | |
Edosuyi Osaze et al. | Antinociceptive and antioxidant activities of Hunteria umbellata stem bark: possible role of the serotonergic, opioidergic and dopaminergic pathways |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |